Supplemental material, sj-docx-1-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatment effect in multiple sclerosis trials by Maria Pia Sormani, Jeremy Chataway, David M Kent and Ruth Ann Marrie in Multiple Sclerosis Journal</p
Supplemental material, sj-docx-1-mso-10.1177_20552173221150370 for Treatment preferences in relation...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-1-mso-10.1177_20552173221147620 for Axonal and myelin changes and the...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatm...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189677 for Enhancing diversity of clinical t...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189670 for Participant diversity in clinical...
Supplemental material, sj-docx-1-msj-10.1177_13524585221125382 for Recurrent disability progression ...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-1-msj-10.1177_13524585221122210 for Leptomeningeal enhancement under ...
Supplemental material, sj-docx-1-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsi...
Supplemental material, sj-docx-1-msj-10.1177_13524585231199084 for Vaccination frequency in people n...
Supplemental material, sj-docx-1-mso-10.1177_20552173221150370 for Treatment preferences in relation...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-1-mso-10.1177_20552173221147620 for Axonal and myelin changes and the...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatm...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189677 for Enhancing diversity of clinical t...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189670 for Participant diversity in clinical...
Supplemental material, sj-docx-1-msj-10.1177_13524585221125382 for Recurrent disability progression ...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-1-msj-10.1177_13524585221122210 for Leptomeningeal enhancement under ...
Supplemental material, sj-docx-1-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsi...
Supplemental material, sj-docx-1-msj-10.1177_13524585231199084 for Vaccination frequency in people n...
Supplemental material, sj-docx-1-mso-10.1177_20552173221150370 for Treatment preferences in relation...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-1-mso-10.1177_20552173221147620 for Axonal and myelin changes and the...